在接受基础和膳食胰岛素治疗的成人2型糖尿病患者（QWINT-4）中，每周一次的α -胰岛素与每日一次的甘精胰岛素U100：一项3期、随机、非劣效性试验

The Lancet Pub Date : 2025-06-22 DOI:10.1016/s0140-6736(25)01069-4

Thomas Blevins MD, Dominik Dahl MD, Federico C Pérez Manghi MD, Sreenivasa Murthy MD, Ramon Ortiz Carrasquillo MD, Xiaoqi Li PhD, Annette M Chang MD, Molly C Carr MD, Michelle Katz MD

{"title":"在接受基础和膳食胰岛素治疗的成人2型糖尿病患者（QWINT-4）中，每周一次的α -胰岛素与每日一次的甘精胰岛素U100：一项3期、随机、非劣效性试验","authors":"Thomas Blevins MD, Dominik Dahl MD, Federico C Pérez Manghi MD, Sreenivasa Murthy MD, Ramon Ortiz Carrasquillo MD, Xiaoqi Li PhD, Annette M Chang MD, Molly C Carr MD, Michelle Katz MD","doi":"10.1016/s0140-6736(25)01069-4","DOIUrl":null,"url":null,"abstract":"Insulin efsitora alfa (efsitora), a once-weekly basal insulin, has the potential to reduce the treatment burden of people with type 2 diabetes who require insulin. We aimed to assess the efficacy and safety of once-weekly efsitora compared with insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial\",\"authors\":\"Thomas Blevins MD, Dominik Dahl MD, Federico C Pérez Manghi MD, Sreenivasa Murthy MD, Ramon Ortiz Carrasquillo MD, Xiaoqi Li PhD, Annette M Chang MD, Molly C Carr MD, Michelle Katz MD\",\"doi\":\"10.1016/s0140-6736(25)01069-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Insulin efsitora alfa (efsitora), a once-weekly basal insulin, has the potential to reduce the treatment burden of people with type 2 diabetes who require insulin. We aimed to assess the efficacy and safety of once-weekly efsitora compared with insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin.\",\"PeriodicalId\":22898,\"journal\":{\"name\":\"The Lancet\",\"volume\":\"48 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0140-6736(25)01069-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)01069-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

每周一次的基础胰岛素（efsitora）有可能减轻需要胰岛素的2型糖尿病患者的治疗负担。我们的目的是评估每周一次的efsitora与甘精胰岛素U100在接受基础胰岛素和膳食胰岛素治疗的成人2型糖尿病患者中的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial

Insulin efsitora alfa (efsitora), a once-weekly basal insulin, has the potential to reduce the treatment burden of people with type 2 diabetes who require insulin. We aimed to assess the efficacy and safety of once-weekly efsitora compared with insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet

自引率

0.00%

发文量